within LGS. an important how Dravet new are expressing to want to begin field I we product potential has have of the our Justin. excited launched the to believe and that you, first treatment and by Thank Epidiolex become
completely V, consistent who government Epidiolex prescribed which on into our company The was DEA the their it on also share call on of the Xst moved November potential been allowing on rescheduling like rescheduled with supply the have outcome ship I have pleased chain. the to last that we first least batches to would action, schedule. the abuse and across affairs the to the States. Once team, the publish initiatives, of rescheduling the with product to that been to quickly state our for rescheduling While two rescheduled, product action low officially DEA able is their are Washington the Schedule the restrictive this took have United state DC for years freely ensure the scheduling Epidiolex. states of days each is the be launched DEA of also assessment full FDA's This working XX to announcement the XX Epidiolex U.S. Epidiolex, of year. of of
at I to XX of average over sales team or am Looking our experience that highly say team rare in is proud neurology, disease, organization, an with epilepsy. this experienced of years
of target plus of extensive launch. speaker for also planned the XXXX. extensive participated Salesforce an and in speaker physicians call. the the been across the The setting clinicians, undertook series live programs rest educate access XX over and November programs we remote completed States. up XX initiated the to support first speaker is to in On broadcast Xth, national United included XX of live sites XXX a broadcast and some have events launch educational which with events week local We total, In
this sponsorship by for very are XXX Advocacy completing scheduled with local events events with of active launch remainder We also Patient the XX year. Organization,
educate caregivers has online array social media of an broadcast, and These as patients. providers, Our extensive print, marketing include team resources. materials the support and resources and to they team developed sales healthcare
both XXX,XXX and of inception a caregivers Since sites patient patients have number and the healthcare our important had professionals. we have designed Web and established these we example, visits professional to of Web sites, and each healthcare For of caregiver sites. to inform over
important of information. role the to Turning medical
manner. of providing with high-quality, Our objective dedicated caring support consistent in-house the caregivers medical an in information team information is both and and for comprehensive a empathetic and center HCPs
continued to and centers from robust clinical presentations our science epilepsy and data data centers disseminate scientific medical in Epidiolex academic liaison medical to the U.S. program the major clinical Our congresses through important at team and
XX We New will epilepsy in Orleans. meeting poster have annual society, American at presentations upcoming the next over week
are to have both we that specific one than the population today; payers Epidiolex. of and prescriptions are don't the commercial provide likely by being metrics month significant launch into reimbursed any filled the I launch try less latter to Epidiolex, As may being pediatric CMS; important due and
authorization community, policy a clients seeing discussions prior and authorization have being already our payer common number A patients the with have prior prior the label syndrome Regarding most failure generally to on we the Dravet standard with a requirement. of pretty coverage with and established AEDs. LGS are
reference we new have previously, with authorization for prior any the it and to call drug we been time that large major like As drug has this some on have the this category national preferred working not take who formulary. on a take unusual a would to to placed does payer stated to initial up Epidiolex as two their antiepileptic I in process make is weeks. with as brand
learning understanding quick work that encouraging requirement. working has the a believe team with prior other think they demand specialist of is positive will and Epidiolex authorization We and as initial are the We coverage note is high, plans I clinics. Epidiolex into it's while level to relatively the epilepsy generated do that that decision-making. important the by Greenwich an face of curve advanced meaningful to major the their reimbursement believe majority reduce feel formulary introduce that we also we
of disease first. syndrome They patients the on and clinicians likely the and We younger have complex focus expect that indicated Dravet LGS will point the to in the of doses. are that before the due mg/kg/day titrating efficacy number to up nature also they line higher concomitant likely titrating titrate that to XX drugs Epidiolex to label at the observing and with guidelines,
receiving X,XXX free have the we the from open previously pivotal are an of label from As of in program clinical stated, trials research currently form approximately expanded access charge product. patients Epidiolex the extension
to to on patients have that such most embark product help of treatment. continuity ensure and these will We program systematic commercial a access to ensure importantly,
physicians subsequent Epidiolex new led to December with December product; timeframe the Having on of numbers a the period. payout. I represents top for universe of quarter. have gain current holidays. previous set and payers are the immediate the are of encouraged With this launches, those successful a we to to through determination I made many expectations the commercial already our reduced primarily of setting the said, we existing target selling wheels States, I by the I'm As Further, in forward in particular, sharing ended say this compassionate and to to focusing likely up two the do for have earnings large during actual and earlier end of payers weeks mentioned first build decisions of have months that physician and working product. that interest this XXXX. coverage is the of days XXXX, important need these selling for with traction launch make November an in in mid coverage with commence the it to to prepared is two from of launch patients such, think that plan to the that due in by year just both major for coverage patients with Xst around here to start from calls. period will successful to determinations executing number that Epidiolex the our Therefore, on favorable you begin is expected and believe is this, Epidiolex successful revenue to quarter is high of company commercial overtime, November there used initially to motion migration level On I about and results we for United quarter against XXst look
non-U.S. and Chris? GW's now an COO, provide ask activities me European Chris Let leads GW's update commercial Tovey, commercialization. to Chris on manufacturing.
